These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

117 related articles for article (PubMed ID: 26509147)

  • 21. Use of ANOVA to estimate inter- and intra-reader variability for a group of readers in thorough QT/QTc studies.
    Natekar M; Mahajan V; Satra A; O'Kelly M; Karnad DR
    Clin Pharmacol Ther; 2008 Mar; 83(3):489-91. PubMed ID: 18183035
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Statistical characteristics of moxifloxacin-induced QTc effect.
    Yan LK; Zhang J; Ng MJ; Dang Q
    J Biopharm Stat; 2010 May; 20(3):497-507. PubMed ID: 20358432
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Enabling robust assessment of QTc prolongation in early phase clinical trials.
    Mehrotra DV; Fan L; Liu F; Tsai K
    Pharm Stat; 2017 May; 16(3):218-227. PubMed ID: 28374497
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Sensitivity of common marmosets to detect drug-induced QT interval prolongation: moxifloxacin case study.
    Komatsu R; Honda M; Holzgrefe HH; Kubo J; Yamada Y; Isobe T; Kimura K; Itoh T; Tamaoki N; Tabo M
    J Pharmacol Toxicol Methods; 2010; 61(3):271-6. PubMed ID: 20097298
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Lack of effect of perampanel on QT interval duration: Results from a thorough QT analysis and pooled partial seizure Phase III clinical trials.
    Yang H; Laurenza A; Williams B; Patten A; Hussein Z; Ferry J
    Epilepsy Res; 2015 Aug; 114():122-30. PubMed ID: 26088895
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Assessment of Interspecies Differences in Drug-Induced QTc Interval Prolongation in Cynomolgus Monkeys, Dogs and Humans.
    Dubois VF; de Witte WE; Visser SA; Danhof M; Della Pasqua O; ;
    Pharm Res; 2016 Jan; 33(1):40-51. PubMed ID: 26553352
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Performance characteristics for some typical QT study designs under the ICH E-14 guidance.
    Hutmacher MM; Chapel S; Agin MA; Fleishaker JC; Lalonde RL
    J Clin Pharmacol; 2008 Feb; 48(2):215-24. PubMed ID: 18199896
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Improving the precision of QT measurements.
    Darpo B; Fossa AA; Couderc JP; Zhou M; Schreyer A; Ticktin M; Zapesochny A
    Cardiol J; 2011; 18(4):401-10. PubMed ID: 21769821
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Measuring the effects of supratherapeutic doses of levofloxacin on healthy volunteers using four methods of QT correction and periodic and continuous ECG recordings.
    Noel GJ; Goodman DB; Chien S; Solanki B; Padmanabhan M; Natarajan J
    J Clin Pharmacol; 2004 May; 44(5):464-73. PubMed ID: 15102866
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Ritonavir 100 mg does not cause QTc prolongation in healthy subjects: a possible role as CYP3A inhibitor in thorough QTc studies.
    Sarapa N; Nickens DJ; Raber SR; Reynolds RR; Amantea MA
    Clin Pharmacol Ther; 2008 Jan; 83(1):153-9. PubMed ID: 17581594
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Effect of lenvatinib (E7080) on the QTc interval: results from a thorough QT study in healthy volunteers.
    Shumaker RC; Zhou M; Ren M; Fan J; Martinez G; Aluri J; Darpo B
    Cancer Chemother Pharmacol; 2014 Jun; 73(6):1109-17. PubMed ID: 24658627
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Statistical analysis methods for QT/QTc prolongation.
    Ma H; Smith B; Dmitrienko A
    J Biopharm Stat; 2008; 18(3):553-63. PubMed ID: 18470763
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Drug-induced QT prolongation when QT interval is measured in each of the 12 ECG leads in men and women in a thorough QT study.
    Panicker GK; Salvi V; Karnad DR; Chakraborty S; Manohar D; Lokhandwala Y; Kothari S
    J Electrocardiol; 2014; 47(2):155-7. PubMed ID: 24388488
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Sensitivity of pharmacokinetic-pharmacodynamic analysis for detecting small magnitudes of QTc prolongation in preclinical safety testing.
    Gotta V; Cools F; van Ammel K; Gallacher DJ; Visser SA; Sannajust F; Morissette P; Danhof M; van der Graaf PH
    J Pharmacol Toxicol Methods; 2015; 72():1-10. PubMed ID: 25556117
    [TBL] [Abstract][Full Text] [Related]  

  • 35. ECG Evaluation as Part of the Clinical Pharmacology Strategy in the Development of New Drugs: A Review of Current Practices and Opportunities Based on Five Case Studies.
    Darpo B; Borin M; Ferber G; Galluppi GR; Hopkins SC; Landry I; Lo A; Rege B; Reyderman L; Sun L; Watanabe T; Xue H; Yasuda S
    J Clin Pharmacol; 2022 Dec; 62(12):1480-1500. PubMed ID: 35665514
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Arrhythmogenic liability screening in cardiovascular safety pharmacology: commonality between non-clinical safety pharmacology and clinical thorough QT (TQT) studies.
    Authier S; Pugsley MK; Troncy E; Curtis MJ
    J Pharmacol Toxicol Methods; 2010; 62(2):83-8. PubMed ID: 20601020
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Differences between study-specific and subject-specific heart rate corrections of the QT interval in investigations of drug induced QTc prolongation.
    Malik M; Hnatkova K; Batchvarov V
    Pacing Clin Electrophysiol; 2004 Jun; 27(6 Pt 1):791-800. PubMed ID: 15189536
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Use of the average baseline versus the time-matched baseline in parallel group thorough QT/QTc studies.
    Meng Z; Quan H; Fan L; Kringle R; Sun G
    J Biopharm Stat; 2010 May; 20(3):665-82. PubMed ID: 20358444
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Loxapine delivered as a thermally generated aerosol does not prolong QTc in a thorough QT/QTc study in healthy subjects.
    Spyker DA; Voloshko P; Heyman ER; Cassella JV
    J Clin Pharmacol; 2014 Jun; 54(6):665-74. PubMed ID: 24375070
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Application of a probabilistic method for the determination of drug-induced QT prolongation in telemetered cynomolgus monkeys: effects of moxifloxacin.
    Holzgrefe HH; Cavero I; Buchanan LV; Gill MW; Durham SK
    J Pharmacol Toxicol Methods; 2007; 55(3):227-37. PubMed ID: 17097307
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.